Sermonix Pharmaceuticals announced this week that two presentations will be given by experts in sexual medicine on its new medication, lasofoxifene, at the annual International Society for the Study of Women’s Sexual Health (ISSWSH) on Feb. 26 and 27 in Charleston, South Carolina.
Sermonix specializes in the advancement and commercialization of emerging late-stage women’s health products. Its product, lasofoxifene, is an investigative selective estrogen receptor modulator (SERM) and is designed to reduce vertebral and non-vertebral fractures in postmenopausal osteoporosis.
When lasofoxifene went through its Phase 3 VVA trials, it progressed substantially statistically and clinically. More than 15,000 women were involved in the global lasofoxifene Phase I-III trials, which included PEARL, OPAL and GARNET trials. During the trials, the drug improved vulvovaginal atrophy (VVA) symptoms and decreased ER+ breast cancer incidence in patients by 83 percent.
Stanley Althof, Ph.D, and Sheryl Kingsberg, Ph.D, will present “A Phase 2 proof of concept program in Female Sexual Arousal Disorder and Hypoactive Sexual Desire Disorder: Patient Characteristics and Implications for Diagnosis and Treatment of Female Sexual Dysfunction." Michael Krychman, M.D., will present “Correlation of Physiologic Markers of Vulvovaginal Atrophy and Symptom Severity in Postmenopausal Women with Genitourinary Syndrome of Menopause.”